Cargando…
DCLK1 immunoreactivity in colorectal neoplasia
INTRODUCTION: Microtubule-associated doublecortin and CaM kinase-like-1 (DCLK1) is a novel candidate marker for intestinal stem cells. The aim of our study was to assess DCLK1 immunoreactivity in colorectal carcinogenesis and its correlation with prognosis. METHODS: DCLK1 immunostaining was performe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340108/ https://www.ncbi.nlm.nih.gov/pubmed/22557932 http://dx.doi.org/10.2147/CEG.S30281 |
_version_ | 1782231433158328320 |
---|---|
author | Gagliardi, Giuseppe Goswami, Monica Passera, Roberto Bellows, Charles F |
author_facet | Gagliardi, Giuseppe Goswami, Monica Passera, Roberto Bellows, Charles F |
author_sort | Gagliardi, Giuseppe |
collection | PubMed |
description | INTRODUCTION: Microtubule-associated doublecortin and CaM kinase-like-1 (DCLK1) is a novel candidate marker for intestinal stem cells. The aim of our study was to assess DCLK1 immunoreactivity in colorectal carcinogenesis and its correlation with prognosis. METHODS: DCLK1 immunostaining was performed in colorectal tissue from 71 patients, including 18 adenomatous polyps, 40 primary adenocarcinomas, and 14 metastatic lesions. Each case was evaluated by a combined scoring method based on the intensity of staining (score 0–3) and the percentage of tissue staining positive (score 0–3). Immunoexpression for DCLK1 was considered as positive when the combined score was 2–6 and negative with a score of 0–1. RESULTS: Overall, 14/18 (78%) of polyps, 30/40 (75%) of primary adenocarcinomas, and 7/14 (50%) of distant metastases were positive for DCLK1. In adenomatous polyps and primary cancer there was no association between DCLK1 staining score and tumor pathology. However, after curative colorectal cancer resection, patients whose tumor had a high (≥5) combined staining score had increased cancer-specific mortality compared to patients with low (0–4) staining score (hazard ratio 5.89; 95% confidence interval: 1.22–28.47; P = 0.027). CONCLUSION: We found that DCLK1 is frequently expressed in colorectal neoplasia and may be associated with poor prognosis. Further studies are necessary to validate the use of DCLK1 as a prognostic marker. |
format | Online Article Text |
id | pubmed-3340108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-33401082012-05-03 DCLK1 immunoreactivity in colorectal neoplasia Gagliardi, Giuseppe Goswami, Monica Passera, Roberto Bellows, Charles F Clin Exp Gastroenterol Original Research INTRODUCTION: Microtubule-associated doublecortin and CaM kinase-like-1 (DCLK1) is a novel candidate marker for intestinal stem cells. The aim of our study was to assess DCLK1 immunoreactivity in colorectal carcinogenesis and its correlation with prognosis. METHODS: DCLK1 immunostaining was performed in colorectal tissue from 71 patients, including 18 adenomatous polyps, 40 primary adenocarcinomas, and 14 metastatic lesions. Each case was evaluated by a combined scoring method based on the intensity of staining (score 0–3) and the percentage of tissue staining positive (score 0–3). Immunoexpression for DCLK1 was considered as positive when the combined score was 2–6 and negative with a score of 0–1. RESULTS: Overall, 14/18 (78%) of polyps, 30/40 (75%) of primary adenocarcinomas, and 7/14 (50%) of distant metastases were positive for DCLK1. In adenomatous polyps and primary cancer there was no association between DCLK1 staining score and tumor pathology. However, after curative colorectal cancer resection, patients whose tumor had a high (≥5) combined staining score had increased cancer-specific mortality compared to patients with low (0–4) staining score (hazard ratio 5.89; 95% confidence interval: 1.22–28.47; P = 0.027). CONCLUSION: We found that DCLK1 is frequently expressed in colorectal neoplasia and may be associated with poor prognosis. Further studies are necessary to validate the use of DCLK1 as a prognostic marker. Dove Medical Press 2012-04-11 /pmc/articles/PMC3340108/ /pubmed/22557932 http://dx.doi.org/10.2147/CEG.S30281 Text en © 2012 Gagliardi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Gagliardi, Giuseppe Goswami, Monica Passera, Roberto Bellows, Charles F DCLK1 immunoreactivity in colorectal neoplasia |
title | DCLK1 immunoreactivity in colorectal neoplasia |
title_full | DCLK1 immunoreactivity in colorectal neoplasia |
title_fullStr | DCLK1 immunoreactivity in colorectal neoplasia |
title_full_unstemmed | DCLK1 immunoreactivity in colorectal neoplasia |
title_short | DCLK1 immunoreactivity in colorectal neoplasia |
title_sort | dclk1 immunoreactivity in colorectal neoplasia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340108/ https://www.ncbi.nlm.nih.gov/pubmed/22557932 http://dx.doi.org/10.2147/CEG.S30281 |
work_keys_str_mv | AT gagliardigiuseppe dclk1immunoreactivityincolorectalneoplasia AT goswamimonica dclk1immunoreactivityincolorectalneoplasia AT passeraroberto dclk1immunoreactivityincolorectalneoplasia AT bellowscharlesf dclk1immunoreactivityincolorectalneoplasia |